Compound information
- Natural Products
- ZC1445086
- Molecular Formula
- C20H27N3O4
- Molecular Weight
- 373.200156344 g/mol
- Structure
-
- IUPAC Name
- tert-butyl (3R)-3-methyl-4-[4-(prop-2-enoylamino)benzoyl]piperazine-1-carboxylate
- InChI
- InChI=1S/C20H27N3O4/c1-6-17(24)21-16-9-7-15(8-10-16)18(25)23-12-11-22(13-14(23)2)19(26)27-20(3,4)5/h6-10,14H,1,11-13H2,2-5H3,(H,21,24)/t14-/m1/s1
- InChI Key
- VCZJOZNUOWLESQ-CQSZACIVSA-N
- SMILES
- C=CC(=O)Nc1ccc(C(=O)N2CCN(C(=O)OC(C)(C)C)C[C@H]2C)cc1
- Source
- ZINC001466624521
Warheads
- Acrylamide
-
- Carbamate
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 27 | Ring Count | 2 |
| Heteroatom Count | 7 | Rotatable Bond Count | 3 |
| Hydrogen Bond Acceptor Count | 4 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 78.95 Å2 | LogP | 2.524 |
| LogS | -3.668 | LogD | 2.751 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.893 | Pgp substrate | 0.032 |
| HIA | 0.964 | F20 % | 0.958 |
| F30 % | 0.391 | Caco-2 | -4.669 |
| MDCK | -4.936 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.954 | PPB | 76.415 |
| VD | 1.056 | Fu | 0.691 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.017 | CYP1A2 substrate | 0.388 |
| CYP2A6 substrate | 0.54 | CYP2B6 substrate | 0.493 |
| CYP2C19 inhibitor | 0.303 | CYP2C19 substrate | 0.791 |
| CYP2C8 substrate | 0.625 | CYP2C9 inhibitor | 0.112 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.033 |
| CYP2D6 substrate | 0.791 | CYP2E1 substrate | 0.871 |
| CYP3A4 inhibitor | 0.005 | CYP3A4 substrate | 1.0 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.613 | CL | 2.772 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.002 | Hepatotoxicity | 0.808 |
| Mutagenicity | 0.067 | Rat Oral Acute Toxicity | 0.052 |
| FDAMDD | 0.451 | Skin Sensitization | 0.769 |
| Carcinogenicity | 0.861 | Eye Corrosion | 0.003 |
| Eye Irritation | 0.404 | Respiratory Toxicity | 0.012 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | -0.175 | IGC50 | 2.561 |
| LC50FM | 1.099 | LC50DM | -0.539 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.54 | NR-AR-LBD | 0.271 |
| NR-AhR | 0.286 | NR-Aromatase | 0.024 |
| NR-ER | 0.397 | NR-ER-LBD | 0.507 |
| NR-PPAR-gamma | 0.297 | SR-ARE | 0.716 |
| SR-ATAD5 | 0.53 | SR-HSE | 0.123 |
| SR-MMP | 0.02 | SR-p53 | 0.174 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.